{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-068011","form_type":"8-K","ticker":"SRZN","cik":"0001824893","company_name":"Surrozen, Inc./DE","filed_at":"2025-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.953688+00:00","generated_at":"2026-05-22T02:04:03.056361+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Surrozen Q1 net loss $27M, cash $101.6M; discontinues SZN-043, pivots to ophthalmology","bullets":["Net loss of $27.0M ($7.43 per share) vs $8.8M ($4.24 per share) in Q1 2024; R&D expenses $6.6M.","Cash increased to $101.6M from $34.6M at year-end 2024, boosted by $76.4M from first tranche of $175M private placement.","Discontinued SZN-043 for severe alcohol-associated hepatitis due to insufficient Phase 1b benefit; shifted focus to ophthalmology.","Expects to file IND for lead candidate SZN-8141 in 2026; FDA clearance triggers $98.6M tranche to fund operations.","Research service revenue $1.0M from TCGFB collaboration; other income $38.0M from non-cash warrant valuation changes."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-068011","json":"https://secwatch.observer/filing/0000950170-25-068011.json","markdown":"https://secwatch.observer/filing/0000950170-25-068011.md","text":"https://secwatch.observer/filing/0000950170-25-068011.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1824893/000095017025068011/0000950170-25-068011-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1824893/000095017025068011/srzn-20250509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T02:04:03.056361+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}